Replies to post #104254 on Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

Funny, To infinity..., I was thinking about the same thing. It's interesting how in the ECCMID Brilacidin presentation (slide 19/24) Dr. Jorgensen discusses the accuracy of PK-PD modeling and dose selection. It's not the first time he's mentioned the value of PK-PD modeling and dose selection. I suspect that this extended Phase 1 for Kevetrin is providing enough PK/PD data to make some pretty good predictions about Kevetrin dose and frequency for upcoming trials.